Clinical Trials Browser

Phase 2/3 × Carcinoma, Non-Small-Cell Lung × Gemcitabine × Clear all

NCT05096663 2025-05-15

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01774578 2020-05-28

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Phase 2/3 Terminated

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT01631357 2019-11-05

CIK

Phase 2/3 Completed

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell

NCT01407822 2018-09-11

EMERGING

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01383148 2017-01-05

TIME

Phase 2/3 Terminated

Carcinoma, Non-Small-Cell Lung

NCT00022009 2013-09-20

Gemcitabine Plus Supportive Care in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms